RyboDyn, Inc. develops immunotherapies targeting the "dark genome" to treat cancer. The company uses a proprietary platform called RyboCypher™ to map the "dark transcriptome and proteome," allowing them to identify and validate previously unknown, disease-specific cryptic proteins.

R3 Bio is focused on developing genetically engineered, brainless "organ sacks" as an alternative to animal testing and a future source of human organs.

ProteomEdge was founded by researchers from the Human Protein Atlas program and the Science for Life Laboratory (SciLifeLab). The company specializes in developing proprietary mass spectrometry (MS) based analysis platforms, offering labeled protein standards for absolute quantification of human blood plasma proteins.

Pinnacle Medicines is focused on discovering oral peptide therapeutics for using AI and proprietary design tools with an emphasis on specializes in immunology and cardiometabolic diseases.

PerturbAI is an AI-driven therapeutics company that emerged from stealth in March 2026, introducing the world's largest in vivo CRISPR atlas, which maps gene function within living tissue. The company uses a dataset of 8 million brain-wide cells, generated in collaboration with NVIDIA and 10x Genomics, to accelerate drug discovery by moving from correlation to causal, brain-wide gene function studies.

Owen Mumford is a prominent medical device manufacturer specializing in the design and production of drug delivery systems, blood sampling devices, and other medical equipment. 

A clinical-stage biopharmaceutical company focused on "immune reset" therapeutics for chronic immune-mediated diseases using T-cell engagers.

A biotechnology company working to convert industrial byproducts into low-footprint, bio-based biodegradable plastic resins and additives using engineered microorganisms.

Oryon Cell Therapies is a clinical-stage biotechnology company focused on developing autologous (patient-derived) neuron replacement medicines to treat Parkinson’s disease and other neurodegenerative disorders. 

Origin Genomics focuses on advancing precision germline gene correction to prevent severe inherited diseases at the earliest stages of life.